New cancer drug RS-0139 tested in humans for first time
NCT ID NCT04261413
First seen Apr 01, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processes it. Researchers also looked for signs of tumor shrinkage and changes in tumor markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi
Ankara, Turkey (Türkiye)
-
Koç University Hospital Phase I Center
Istanbul, Turkey (Türkiye)
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RS-0139 (a tumor-targeted prodrug)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 16 participants, focused on safety and dosing. It is too soon to know if the drug will effectively shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.